News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation
Cryoballoon (CB)-guided pulmonary vein isolation (PVI) represents a cornerstone in the treatment of atrial fibrillation (AF). Recently, a novel balloon-guided single shot device (POLARx, Boston Scientific) was designed. Our study aimed to compare the efficacy, safety and characteristics of the novel...
Published in: | Journal of Cardiovascular Development and Disease |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Text |
Language: | English |
Published: |
Multidisciplinary Digital Publishing Institute
2022
|
Subjects: | |
Online Access: | https://doi.org/10.3390/jcdd9010016 |
id |
ftmdpi:oai:mdpi.com:/2308-3425/9/1/16/ |
---|---|
record_format |
openpolar |
spelling |
ftmdpi:oai:mdpi.com:/2308-3425/9/1/16/ 2023-08-20T04:04:20+02:00 News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation Denise Guckel Philipp Lucas Khuraman Isgandarova Mustapha El Hamriti Leonard Bergau Thomas Fink Vanessa Sciacca Guram Imnadze Martin Braun Moneeb Khalaph Georg Nölker Philipp Sommer Christian Sohns 2022-01-08 application/pdf https://doi.org/10.3390/jcdd9010016 EN eng Multidisciplinary Digital Publishing Institute Electrophysiology and Cardiovascular Physiology https://dx.doi.org/10.3390/jcdd9010016 https://creativecommons.org/licenses/by/4.0/ Journal of Cardiovascular Development and Disease; Volume 9; Issue 1; Pages: 16 atrial fibrillation catheter ablation cryoballoon single-shot ablation devices Text 2022 ftmdpi https://doi.org/10.3390/jcdd9010016 2023-08-01T03:46:59Z Cryoballoon (CB)-guided pulmonary vein isolation (PVI) represents a cornerstone in the treatment of atrial fibrillation (AF). Recently, a novel balloon-guided single shot device (POLARx, Boston Scientific) was designed. Our study aimed to compare the efficacy, safety and characteristics of the novel CB system with the established one (Arctic Front Advance (Pro), AFA, Medtronic). A total number of 596 patients undergoing CB-guided ablation for AF were included. 65 patients (65.0 ± 11.6, 31% female) undergoing PVI with the POLARx were compared to a cohort of 531 consecutive patients (63.0 ± 27.9, 25% female) treated with AFA. Acute PVI was achieved in all patients (n = 596, 100%). Total procedure duration (POLARx 113.3 ± 23.2 min, AFA 100.9 ± 21.3 min; p < 0.001) and fluoroscopy time (POLARx 10.5 ± 5.9 min, AFA 4.8 ± 3.6 min; p < 0.001) were significantly longer in the POLARx group. The POLARx balloon achieved significantly lower nadir temperatures (POLARx −57.7 ± 0.9 °C, AFA −45.1 ± 2.6 °C; p < 0.001) and a significantly higher percentage of pulmonary veins successfully isolated with the first freeze (p = 0.027 *). One major complication occurred in the POLARx (2%) and three (1%) in the AFA group. Both ablation systems are comparably safe and effective. AF ablation utilizing the POLARx system is associated with longer procedure and fluoroscopy times as well as lower nadir temperatures. Text Arctic MDPI Open Access Publishing Arctic Journal of Cardiovascular Development and Disease 9 1 16 |
institution |
Open Polar |
collection |
MDPI Open Access Publishing |
op_collection_id |
ftmdpi |
language |
English |
topic |
atrial fibrillation catheter ablation cryoballoon single-shot ablation devices |
spellingShingle |
atrial fibrillation catheter ablation cryoballoon single-shot ablation devices Denise Guckel Philipp Lucas Khuraman Isgandarova Mustapha El Hamriti Leonard Bergau Thomas Fink Vanessa Sciacca Guram Imnadze Martin Braun Moneeb Khalaph Georg Nölker Philipp Sommer Christian Sohns News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation |
topic_facet |
atrial fibrillation catheter ablation cryoballoon single-shot ablation devices |
description |
Cryoballoon (CB)-guided pulmonary vein isolation (PVI) represents a cornerstone in the treatment of atrial fibrillation (AF). Recently, a novel balloon-guided single shot device (POLARx, Boston Scientific) was designed. Our study aimed to compare the efficacy, safety and characteristics of the novel CB system with the established one (Arctic Front Advance (Pro), AFA, Medtronic). A total number of 596 patients undergoing CB-guided ablation for AF were included. 65 patients (65.0 ± 11.6, 31% female) undergoing PVI with the POLARx were compared to a cohort of 531 consecutive patients (63.0 ± 27.9, 25% female) treated with AFA. Acute PVI was achieved in all patients (n = 596, 100%). Total procedure duration (POLARx 113.3 ± 23.2 min, AFA 100.9 ± 21.3 min; p < 0.001) and fluoroscopy time (POLARx 10.5 ± 5.9 min, AFA 4.8 ± 3.6 min; p < 0.001) were significantly longer in the POLARx group. The POLARx balloon achieved significantly lower nadir temperatures (POLARx −57.7 ± 0.9 °C, AFA −45.1 ± 2.6 °C; p < 0.001) and a significantly higher percentage of pulmonary veins successfully isolated with the first freeze (p = 0.027 *). One major complication occurred in the POLARx (2%) and three (1%) in the AFA group. Both ablation systems are comparably safe and effective. AF ablation utilizing the POLARx system is associated with longer procedure and fluoroscopy times as well as lower nadir temperatures. |
format |
Text |
author |
Denise Guckel Philipp Lucas Khuraman Isgandarova Mustapha El Hamriti Leonard Bergau Thomas Fink Vanessa Sciacca Guram Imnadze Martin Braun Moneeb Khalaph Georg Nölker Philipp Sommer Christian Sohns |
author_facet |
Denise Guckel Philipp Lucas Khuraman Isgandarova Mustapha El Hamriti Leonard Bergau Thomas Fink Vanessa Sciacca Guram Imnadze Martin Braun Moneeb Khalaph Georg Nölker Philipp Sommer Christian Sohns |
author_sort |
Denise Guckel |
title |
News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation |
title_short |
News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation |
title_full |
News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation |
title_fullStr |
News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation |
title_full_unstemmed |
News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation |
title_sort |
news from the cold chamber: clinical experiences of polarx versus arctic front advance for single-shot pulmonary vein isolation |
publisher |
Multidisciplinary Digital Publishing Institute |
publishDate |
2022 |
url |
https://doi.org/10.3390/jcdd9010016 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Journal of Cardiovascular Development and Disease; Volume 9; Issue 1; Pages: 16 |
op_relation |
Electrophysiology and Cardiovascular Physiology https://dx.doi.org/10.3390/jcdd9010016 |
op_rights |
https://creativecommons.org/licenses/by/4.0/ |
op_doi |
https://doi.org/10.3390/jcdd9010016 |
container_title |
Journal of Cardiovascular Development and Disease |
container_volume |
9 |
container_issue |
1 |
container_start_page |
16 |
_version_ |
1774714726009274368 |